Insulet Corporation designs, manufactures, and sells Omnipod, a proprietary system of tubeless, disposable insulin delivery pods for people with insulin-dependent diabetes, particularly those with Type 1 or insulin-requiring Type 2 diabetes. The company's main products—Omnipod 5 (an automated system that integrates with continuous glucose monitors and adjusts insulin dosing via algorithm), Omnipod DASH (a wireless-enabled system controlled by a handheld device), and Classic Omnipod—are sold globally through wholesalers, pharmacies, and distributors to patients typically covered by commercial insurance or government programs, while the company also manufactures delivery pods for Amgen's oncology treatment kit. Revenue comes from direct sales of insulin delivery systems to consumers through these distribution channels and from manufacturing partnerships, with reimbursement secured through contracts with national payors and government agencies, leveraging the pod's tubeless design and clinical benefits to justify pricing.